Pfizer's smoking-cessation drug Chantix edged out GlaxoSmithKline's nicotine patch NicoDerm CQ in a study published today. The study was funded by Pfizer, and it's a bit of good news for a drug that's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback